GHK-Cu (Copper Peptide) vs Tesamorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
GHK-Cu (Copper Peptide)
GHK-Cu is a naturally occurring copper peptide found in human plasma, saliva, and urine. It plays important roles in wound healing, tissue repair, and has shown anti-aging properties in research.
Full details →Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Side-by-Side Comparison
| Aspect | GHK-Cu (Copper Peptide) | Tesamorelin |
|---|---|---|
| Dose Range | 1 mg–2 mg | 2 mg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 4–8 weeks | 8–52 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Attracts immune cells and fibroblasts to wound sites, stimulates collagen and glycosaminoglycan synthesis, promotes angiogenesis, and has antioxidant effects. Modulates gene expression related to tissue repair. | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. |
| Typical Dosage | Topical: Applied as serum or cream 1-2 times daily. Injectable: 1-2mg daily for research purposes. Microneedling protocols often use 0.5-1%. | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. |
| Administration | Most commonly used topically for skin applications. Can be injected subcutaneously for systemic effects. Often combined with microneedling for enhanced skin penetration. | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. |
| Side Effects | Topical use is generally well-tolerated. May cause temporary skin irritation or redness in sensitive individuals. Injectable use may cause injection site reactions. | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. |
| Best For |
Key Differences
Unique to GHK-Cu (Copper Peptide):
Unique to Tesamorelin:
Key Studies
GHK-Cu (Copper Peptide)
- Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs.
Research square, 2026
- Glycyl-L-histidyl-L-lysine-Cu2(+) (GHK-Cu) Attenuates CuSO(4) or LPS induced-inflammation in Zebrafish larvae model.
European journal of pharmacology, 2026
- The Regenerative Potential of GHK-Cu in Aesthetic Medicine.
Aesthetic surgery journal, 2026
Tesamorelin
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
BMJ open, 2026
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
The Journal of infectious diseases, 2025
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
AIDS (London, England), 2024
Ready to Learn More?
Looking for trusted sources?